Cargando…
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of advers...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498261/ https://www.ncbi.nlm.nih.gov/pubmed/36140493 http://dx.doi.org/10.3390/diagnostics12092091 |
_version_ | 1784794714403241984 |
---|---|
author | Albarrán-Artahona, Víctor Laguna, Juan-Carlos Gorría, Teresa Torres-Jiménez, Javier Pascal, Mariona Mezquita, Laura |
author_facet | Albarrán-Artahona, Víctor Laguna, Juan-Carlos Gorría, Teresa Torres-Jiménez, Javier Pascal, Mariona Mezquita, Laura |
author_sort | Albarrán-Artahona, Víctor |
collection | PubMed |
description | Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of adverse events, characterized by a myriad of diverse manifestations affecting nearly every organ and system of the body, including the endocrine, nervous, cardiac, respiratory and gastrointestinal systems. Uncommon adverse events, defined as those occurring in less than 1% of patients, comprise an even more heterogeneous group of diseases that are being seen more recurrently as the use of immune check-point inhibitors increases and indications spread in different tumor types and stages. Here, we comprehensively review some uncommon, but exceedingly important, immune-related adverse events, with special emphasis in the clinical approach and diagnostic workup, aiming to reunite the evidence published previously, allowing an increase in awareness and knowledge from all specialists implicated in the diagnosis, treatment, and care of cancer patients treated with immunotherapy. |
format | Online Article Text |
id | pubmed-9498261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94982612022-09-23 Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy Albarrán-Artahona, Víctor Laguna, Juan-Carlos Gorría, Teresa Torres-Jiménez, Javier Pascal, Mariona Mezquita, Laura Diagnostics (Basel) Review Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of adverse events, characterized by a myriad of diverse manifestations affecting nearly every organ and system of the body, including the endocrine, nervous, cardiac, respiratory and gastrointestinal systems. Uncommon adverse events, defined as those occurring in less than 1% of patients, comprise an even more heterogeneous group of diseases that are being seen more recurrently as the use of immune check-point inhibitors increases and indications spread in different tumor types and stages. Here, we comprehensively review some uncommon, but exceedingly important, immune-related adverse events, with special emphasis in the clinical approach and diagnostic workup, aiming to reunite the evidence published previously, allowing an increase in awareness and knowledge from all specialists implicated in the diagnosis, treatment, and care of cancer patients treated with immunotherapy. MDPI 2022-08-29 /pmc/articles/PMC9498261/ /pubmed/36140493 http://dx.doi.org/10.3390/diagnostics12092091 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Albarrán-Artahona, Víctor Laguna, Juan-Carlos Gorría, Teresa Torres-Jiménez, Javier Pascal, Mariona Mezquita, Laura Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy |
title | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy |
title_full | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy |
title_fullStr | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy |
title_full_unstemmed | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy |
title_short | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy |
title_sort | immune-related uncommon adverse events in patients with cancer treated with immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498261/ https://www.ncbi.nlm.nih.gov/pubmed/36140493 http://dx.doi.org/10.3390/diagnostics12092091 |
work_keys_str_mv | AT albarranartahonavictor immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy AT lagunajuancarlos immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy AT gorriateresa immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy AT torresjimenezjavier immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy AT pascalmariona immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy AT mezquitalaura immunerelateduncommonadverseeventsinpatientswithcancertreatedwithimmunotherapy |